Ensign Peak Advisors
RPRX icon

Ensign Peak Advisors’s Royalty Pharma RPRX Stock Holding History

Ensign Peak Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.9M Sell
426,592
-506,058
-54% -$26.3M 0.04% 287
2026
Q1 		$44.7M Buy
932,650
+142,348
+18% +$6.23M 0.08% 195
2025
Q4 		$30.5M Sell
790,302
-16,550
-2% -$631K 0.05% 241
2025
Q3 		$28.5M Buy
806,852
+65,816
+9% +$2.38M 0.05% 263
2025
Q2 		$26.7M Buy
741,036
+461,147
+165% +$15.3M 0.05% 271
2025
Q1 		$8.71M Buy
279,889
+69,918
+33% +$2.22M 0.02% 498
2024
Q4 		$5.36M Sell
209,971
-1,208
-0.6% -$32K 0.01% 630
2024
Q3 		$5.97M Buy
211,179
+39,483
+23% +$1.09M 0.01% 574
2024
Q2 		$4.53M Sell
171,696
-5,771
-3% -$160K 0.01% 651
2024
Q1 		$5.39M Buy
177,467
+47,642
+37% +$1.4M 0.01% 617
2023
Q4 		$3.65M Buy
129,825
+7,004
+6% +$192K 0.01% 708
2023
Q3 		$3.33M Sell
122,821
-719,719
-85% -$21.4M 0.01% 676
2023
Q2 		$25.9M Sell
842,540
-28,274
-3% -$958K 0.05% 257
2023
Q1 		$31.4M Sell
870,814
-273,327
-24% -$10.1M 0.07% 230
2022
Q4 		$45.2M Buy
1,144,141
+466,225
+69% +$19.5M 0.1% 179
2022
Q3 		$27.2M Buy
677,916
+579,802
+591% +$24.8M 0.07% 230
2022
Q2 		$4.12M Buy
98,114
+6,729
+7% +$276K 0.01% 593
2022
Q1 		$3.56M Buy
91,385
+40,440
+79% +$1.59M 0.01% 682
2021
Q4 		$2.03M Buy
+50,945
New +$1.98M ﹤0.01% 946
2021
Q3 		– Sell
-2,530
Closed -$104K – 1875
2021
Q2 		$104K Sell
2,530
-29,370
-92% -$1.25M ﹤0.01% 1780
2021
Q1 		$1.39M Buy
31,900
+20,344
+176% +$965K ﹤0.01% 1283
2020
Q4 		$578K Buy
11,556
+9,881
+590% +$419K ﹤0.01% 1573
2020
Q3 		$70K Buy
+1,675
New +$71.9K ﹤0.01% 1718

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ensign Peak Advisors's RPRX Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Royalty Pharma (RPRX) stake by 54% in Q2 2026, selling an estimated $26.3M and leaving 426,592 shares worth $23.9M. The position accounts for 0.04% of the portfolio, ranked #287.

Ensign Peak Advisors first reported a position in RPRX in Q3 2020 and has held it in 23 quarters since. The position peaked at $45.2M in Q4 2022. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Ensign Peak Advisors held 426,592 shares of Royalty Pharma worth $23.9M as of Q2 2026.
  • Ensign Peak Advisors sold 506,058 Royalty Pharma shares in Q2 2026, an estimated $26.3M.
  • Royalty Pharma made up 0.04% of Ensign Peak Advisors's portfolio in Q2 2026, its #287 holding.
  • Ensign Peak Advisors first reported a position in Royalty Pharma in Q3 2020 and has held it in 23 quarters since.
  • Ensign Peak Advisors's Royalty Pharma position peaked at $45.2M in Q4 2022.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.